Comparision between phenobarbitone and levetiracetam as the intial anti convulsant in treating preterm neonatal seizures

Comparision between phenobarbitone and levetiracetam as the intial anti convulsant in preterm neonatal seizures-a randomized control trail

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2021/02/031290

Enrollment

106

Registered

2021-02-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: P90- Convulsions of newborn

Interventions

Intervention1: control of seizure by using phenobarbitone and levetiracetam as anticonvusant: Primary outcome is measured by seizure cessation in first 24 hours. Route of administration- Intravenous D

Eligibility

Inclusion criteria

Inclusion criteria: Neonate with gestational age

Exclusion criteria

Exclusion criteria: Multiple congenital malformation, Seizure secondary to hypoglycemia and hypocalcemia controlled with glucose or calcium bolus respectively

Design outcomes

Primary

Measure	Time frame
Cessation of seizure in first 24 hours of seizureTimepoint: 24 hours	—

Secondary

Measure	Time frame
Clinical response based on the etiology of seizure.Timepoint: 1 month	—

Countries

India

Contacts

Public ContactGummalla Gyandeep

KALINGA INSTITUTE OF MEDICAL SCIENCES

doc.sant@yahoo.co.in9778182963

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026